# SCID-X1 Gene Therapy Via Intravenous Lentiviral (Ivlv-X1) Injection

> **NCT03217617** · PHASE1,PHASE2 · RECRUITING · sponsor: **Shenzhen Geno-Immune Medical Institute** · enrollment: 10 (estimated)

## Conditions studied

- SCID, X-Linked

## Interventions

- **BIOLOGICAL:** Direct intravenous injection of ivlv-X1 lentiviral vector

## Key facts

- **NCT ID:** NCT03217617
- **Lead sponsor:** Shenzhen Geno-Immune Medical Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-30
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2025-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03217617

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03217617, "SCID-X1 Gene Therapy Via Intravenous Lentiviral (Ivlv-X1) Injection". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03217617. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*